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case report
Clinical follow-up of two Brazilian 
subjects with glucokinase-MODY  
(MODY2) with description 
of a novel mutation
Seguimento clínico de dois pacientes brasileiros com MODY-
glicoquinase (MODY2) e descrição de uma nova mutação
Thais DellaManna1, Magnus R. da Silva2, Antonio Roberto 
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SUMMARY
Mutations in the glucokinase gene (GCK) account for many cases of monogenic diabetes fea-
turing maturity-onset diabetes of the young type 2 (MODY2). The clinical pattern of this form 
of hyperglycemia is rather stable, with a slight elevation in blood glucose, which is usually 
not progressive. Patients rarely require pharmacological interventions and microvascular com-
plications related to diabetes are unusual. We describe the clinical follow-up of two cases of 
MODY2 with two different mutations in GCK gene, one in exon 7, p.Glu265Lys (c.793 G> A), 
which has been previously described, and a novel one, in exon 2, p.Ser69Stop (c. 206C> G). The 
clinical course of both cases shows similarity in metabolic control of this form of diabetes over 
the years. Arq Bras Endocrinol Metab. 2012;56(8):490-5
SUMáRio
Mutações no gene da glicoquinase (GCK) são determinantes de uma forma de diabetes mono-
gênico denominada de MODY2 (maturity-onset diabetes of the young, tipo 2). O padrão clínico 
dessa forma de distúrbio glicêmico é bastante estável, com hiperglicemia leve, geralmente não 
progressiva. Intervenções farmacológicas raramente são necessárias e complicações crônicas 
secundárias ao diabetes são infrequentes. Descrevemos o acompanhamento clínico de dois 
casos de MODY2 com duas mutações diferentes, uma no éxon 7, p.Glu265Lys (c.793 G>A) já 
descrita anteriormente, e outra inédita no éxon 2 p.Ser69Stop (c. 206C>G). A evolução clínica 
de ambos os casos demonstra uma semelhança no padrão metabólico dessa forma de diabetes 
ao longo dos anos. Arq Bras Endocrinol Metab. 2012;56(8):490-5
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iNTRoDUCTioN
Maturity onset diabetes of the young (MODY) re-fers to a group of clinically heterogeneous he-
reditary forms of diabetes that are defined at the mo-
lecular genetic level by mutations in different genes. 
All subtypes show beta-cell dysfunction associated with 
defects in insulin secretion, usually with young-onset 
of diabetes (childhood, adolescence, or young adults), 
autosomal dominant inheritance (presence of three 
generations of the same affected lineage) with variable 
clinical features depending on the mutated gene (1-3). 
MODY is one of the monogenic forms of diabetes to be 
distinguished from the polygenic types of diabetes, es-
pecially type 1 and type 2, which involve more complex 
combinations of genetic and environmental factors. At 
least seven forms of MODY have been described by 
molecular genetic studies of diabetes, and are related to 
mutations in Glucokinase (GCK), HNF1A, HNF4A, 
HNF1B, NEUROD1, PDX1, and INS genes, with dif-
ferent clinical presentations. Identification of a MODY 
mutation is important for correct diagnosis, appropri-
ate genetic counseling, evaluation of prognosis, and 
selection of the best treatment (4,5). MODY is rare, 
with an estimated prevalence between 0.3% and 2.4% 
of the diabetes cases, although these figures are con-
sidered underestimations; mutations in HNF1A and 
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GCK genes account for approximately 70% of cases in 
all populations studied (3,6), including in Brazil (7-9).
Glucokinase (GCK) belongs to the hexokinase fam-
ily of enzymes, and catalyses the conversion of glucose 
to glucose-6-phosphate in the first reaction of the gly-
colytic pathway (10). GCK plays a major role in the 
regulation of insulin release and has been termed the 
glucose sensor of pancreatic beta-cells because of its 
ability to alter glucose phosphorylation rates over a 
range of physiological glucose concentrations (11). The 
key regulatory role of GCK in the pancreatic beta-cells 
explains why mutations in this gene can result in both 
hyper- and hypoglycemia. For instance, gain-of-func-
tion heterozygous GCK mutations have been identified 
in patients with congenital hyperinsulinism (CHI) char-
acterized by inappropriate oversecretion of insulin de-
spite hypoglycemia (12). Meanwhile, a total of twelve 
GCK loss-of-function mutations have been reported in 
permanent neonatal diabetes mellitus (PNDM). 
The clinical features that suggest the diagnosis of 
MODY2 are: a) persistent and stable fasting hypergly-
cemia over a period of months or years; b) glycated he-
moglobin (HbA1c) frequently just below or just above 
the upper limit of normal; c) small blood glucose incre-
ment (less than 60 mg/dL) after an oral glucose over-
load test (2hr glucose – fasting glucose); d) parents may 
have diabetes or at least one parent may have mildly 
raised fasting blood glucose; it is important to test fast-
ing glucose in apparently unaffected parents (13,14). 
Existence of heterogeneity in the clinical phenotype 
of patients carrying GCK mutations has already been 
described, including uncommon presentations such as 
overt neonatal hyperglycemia, marked postprandial hy-
perglycemia, glucosuria, and even ketoacidosis (15-17). 
However, overall, the pattern of mild hyperglycemia 
is usually quite stable in most patients. Microvascular 
complications are very unusual in GCK-MODY, and 
pharmacological treatment is rarely needed, since most 
cases are managed by diet alone (5,13,18,19).
MODY diagnosis is defined by molecular genetics 
and predicts disease prognosis, besides identifying risk 
of diabetes in family members. However, genetic test-
ing is expensive, so careful consideration is required 
when determining which patients should be tested (6). 
The aim of this study was to report the clinical 
follow-up of two Brazilian patients with heterozygous 
GCK mutations, since the natural course of MODY2 is 
still unknown within our population. We also described 
a new mutation in GCK gene.
PATiENTS AND METHoDS
Clinical and laboratory data were collected from each 
patient’s records. The following biochemical param-
eters were measured on fasting blood samples: plasma 
glucose (FPG) by enzymatic method; cholesterol and 
triglycerides by colorimetric enzymatic method; HbA1c 
by high performance liquid chromatography (HPLC); 
serum fasting insulin, serum fasting C-peptide, anti-
glutamic acid decarboxylase (GADA), anti-islet cell 
(ICA512) and anti-insulin (IAA) by radioimmunoassay. 
Oral glucose tolerance test (OGTT) was evaluated in 
fasting blood samples, and 2 hours after an oral glucose 
dose of 0.75 g/kg body weight (maximum 75 g). Ho-
meostasis model assessment (HOMA) indexes of beta-
cell function (%B) and insulin sensitivity (%S) were com-
puted with the HOMA Calculator – version 2.2 (20). 
Genetic testing of case 1 was performed in Exeter, 
UK, and of case 2, in Unifesp, Brazil. Genomic DNA 
was extracted from peripheral blood leukocytes by stan-
dard procedures; exons 1A-10 and exon-intron bound-
aries of the GCK gene were screened for mutation by 
direct sequencing using Big Dye Terminator on ABI 
PRISM 3131XL Genetic Analyzer (Applied Biosys-
tems, UK). Polymerase chain reaction (PCR) primers 
were supplied on demand.
Parents of both subjects gave their written informed 
consent for genetic analysis and disclosure of the re-
sults. The research was approved by the Ethics Com-
mittee of Escola Paulista de Medicina, Unifesp.
Patient 1 
The index patient was a boy, the only child to non-con-
sanguineous parents, born at term with a birth weight of 
2.900 g (SDS -1.08) and length of 48 cm (SDS -0.74), 
whose growth and neurological development were 
normal. At 11 years of age, during laboratory tests for 
the investigation of tonsillitis, he showed fasting blood 
glucose level of 125 mg/dL. The test  was repeated a 
few days later and resulted in 123 mg/dL. OGTT was 
performed with the following values: fasting, 112 mg/
dL and 2 h post-load: 151 mg/dL, consistent with the 
American Diabetes Association (ADA) criteria for im-
paired fasting glucose and impaired glucose tolerance 
(pre-diabetes) (21). His pubertal development was 
normal for age, and no other health problems were dis-
closed in physical examination. In his family history, the 
father reported impaired fasting blood glucose level of 
110 mg/dL, which could not be confirmed, and cases 
of diabetes were denied. 
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Laboratory investigation demonstrated negative re-
sults for anti-glutamic acid decarboxylase (GADA), anti-
islet cell (ICA512) and anti-insulin (IAA) self-antibodies. 
Fasting C-peptide levels showed good pancreatic reserve 
(1.4 ng/mL; reference value: 1.1-4.4 ng/mL), and 
HbA1C was 6.1% (reference value: 4.8-5.9%). Based on 
his clinical presentation, the hypothesis of MODY2 was 
formed. Sequencing of the GCK gene identified a muta-
tion in exon 7, p.Glu265Lys (c.793 G>A). The patient 
was advised to perform regular physical activity for weight 
maintenance. Clinical follow-up demonstrated stable fast-
ing blood glucose, and HbA1C levels around 6.3% (rang-
ing from 5.9% to 6.8%; HPLC) in a period of more than 
9 years. He had normal pubertal development with no 
worsening of glycemic control (Table 1). No medica-
tion was prescribed throughout this period. The patient 
remained very active, always practicing regular physical 
activity, maintaining normal weight and body mass index 
(BMI). His parents did not want to perform genetic tests. 
Patient 2
The proband was a girl, the second child of a non-
consanguineous parents, born at 38 weeks of gestation, 
with a birth weight of 2.740 g (SDS -1.29), length of 
46 cm (SDS -1.44). The mother was diagnosed with 
hypothyroidism and gestational diabetes, and treated 
with levothyroxine and insulin; she remained diabetic 
after delivery, with irregular use of metformin. Her fa-
ther was obese and the maternal great-grandmother, 
grandmother, and grandfather had diabetes treated 
with sulphonylurea. The postnatal course was uncom-
plicated but growth retardation was observed during 
the first 6 months of life, and mild hyperglycemia was 
detected in the laboratory work-up (Table 2). At 18 
months of age, type 1 diabetes-associated self-antibod-
ies (ICA512, GADA, IAA) were negative, C-peptide 
level was 0.7 ng/mL, HbA1c was 6.6% and fasting 
blood glucose was 136 mg/dL. The hypothesis of 
MODY2 was formed, and the family was advised about 
the importance of a healthy lifestyle with balanced diet 
and regular physical activity for better prognosis. How-
ever, after 2 years of age, she was started on cafeteria 
food and her weight gain was progressively greater, de-
spite her growth rate remaining stable, in the familial 
growth pattern (SDS -1.74) (Figure 1). Some episodes 
of postprandial hyperglycemia (197; 180; 201 mg/
dL) were detected by self-monitoring of blood glucose, 
without glucosuria. Serial OGTTs were performed and 
the results were consistent with the ADA criteria for 
impaired fasting glucose and impaired glucose toler-
ance (pre-diabetes) in most occasions (21) (Table 2). 
During her clinical follow-up throughout the next 8 
years, she maintained fasting blood glucose between 
117-132 mg/dL and HbA1c between 6.6%-6.8% 
(Table 2). Recently, she started pubertal development 
(Tanner B1P2) at the age of 10 years and 3 months, 
with bone age of 11 years. Sequencing of the GCK has 
recently identified a nonsense mutation p.Ser69Stop 
(c. 206C>G) in the proband and her mother. Her fa-
ther, without history of diabetes, showed no mutation.
Table 1. Clinical follow-up of patient 1 from 13 to 21 years old with biochemical analysis and fundoscopy
Age (years-months) 13y 14y-9m 15y-9m 16y 16y-6m 17y 19y-1m 20y 21y-6m
Weight (kg) 63 70 70
Height (cm) 182 186 187
BMI (kg/m2) 19 20.3 20
Fasting blood glucose (75-99 mg/dL)* 121 116 121 121 134 120 134 126 115
Fasting plasma insulin (2-25 µUI/mL)* 9.1 5.5
HOMA
IR
 /HOMA
S 
(%) 1.3/79.8 0.8/ 131.4
HOMA
beta
 (%) 64.7 46.5
HbA1c (4.8-5.9%) 6.3 6.1 6.6 6.8 6.5 6.3 6.6 6.5 5.9
C-peptide (1.1-4.4 ng/mL)* 1.3 1.03 0.98 1.5
Cholesterol (< 170 mg/dL)* 167
HDL cholesterol (≥ 35 mg/dL)* 33
LDL cholesterol (< 110 mg/dL)* 68
Triglycerides (< 130 mg/dL)* 70 66 66
Microalbuminuria (< 20 µg/min)* Normal Normal Normal
Fundoscopy Normal Normal Normal
* Reference values.
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Table 2. Clinical follow-up of patient 2 from birth to 10 years old with biochemical analysis and fundoscopy
Age (years-months) Birth 8m 1y 4y-10m 5y-11m 6y-6m 7y-9m 8y-6m 9y-6m 10y-6m
Weight (kg)
SDS
2.740
-1.29
7.040
-1.47
8.700
-0.99
21.5
+1.24
25
+1.26
29.3
+1.6
32
+1.27
34.6
+1.16
38
+0.96
46
+1.33
Height (cm) SDS 46
-1.44
62
-2.57
68
-2.13
101
-1.26
109
 -1.08
112.5 
-1.14
117.5
-1.59
120.5
-1.73
124.5
-1.78
129.5
-1.5
BMI-SDS +2.31 +2.16 +2.15 +2.13 +2.02 +2.01 +2.18
Fasting blood glucose (75-99 mg/dL)* 108 133 132 117 131 126 122 126 126
120-min blood glucose (<140 mg/dL)* 148 127 155
Fasting plasma insulin (2-25 µUI/mL)* 7.55 3.49 11.1 6.97 17.0
120-min plasma insulin (µUI/mL)* 15.16 14.93 67.0
HOMA
IR
 /HOMA
S 
(%) 1.1 /93.3 0.5/205.5 1.6 /64.0 1.0/101.9 2.3/42.6
HOMA
beta
 (%) 44.2 33.0 58.8 45.8 85.7
HbA1c (4.8-5.9%) 6.6 6.6 6.8 6.8 6.6 6.8 6.7 6.9
C-peptide (1.1-4.4 ng/mL)* 1.97 1.46
HDL cholesterol (≥ 40 mg/dL)* 59 47 43
LDL cholesterol (<110 mg/dL)* 97 82 11
Triglycerides (< 100 mg/dL)* 41 36 48
IGF1 (20-200 ng/mL)* 49 
Microalbuminuria (< 20 µg/min) 4 4 4 
Fundoscopy Normal Normal
* Reference values.
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Figure 1. Growth chart of a patient with MODY2.
DiSCUSSioN
We describe here the clinical follow-up of two GCK-
MODY pediatric patients whose metabolic control was 
uneventful without diabetes-related complications. 
Molecular analysis demonstrated a missense mutation 
p.Glu265Lys (c.793 G>A) in patient 1, which has al-
ready been described in Italian, Spanish, and British 
populations (22-24). Previous functional studies dem-
onstrated that this mutation strongly affects protein 
stability (25). In patient 2, a novel nonsense mutation 
p.Ser69Stop (c. 206C>G) in exon 2 was identified in 
the patient and her mother, thus demonstrating the 
co-segregation of this mutation and diabetes mellitus 
phenotype.
A total of 620 GCK mutations have been identified 
in 1,441 families with PNDM, MODY, or CHI. Muta-
tions are distributed throughout the gene and no com-
mon mutations or “hot spots” have been found (24). 
All MODY2 cases are made up of heterozygous for 
nonsense, missense, or frameshift mutations and result 
in a deficiency of GCK activity (26-29). More than 50 
mutations were functionally characterized, and most of 
MODY2-clinical follow-up
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them alter the kinetics of the enzyme. In other muta-
tions where kinetics was normal, the mutational mecha-
nism may be related to the effect on enzyme stability 
(as in our case 1), or binding to regulatory molecules 
(24). There is no clear association between phenotype 
(i.e., insulin secretion) and genotype (including type, 
topography) in GCK-MODY patients (30).
In an 11-year period of follow-up, it was observed 
that glucose tolerance of MODY2 adult subjects may 
remain stable for many years, probably because of the 
stability of the glucokinase-related beta-cell defect. 
However, if or when insulin resistance develops, the 
beta-cell defect may impair the increase in insulin secre-
tion, and may result in deterioration of glucose toler-
ance (31). Of note, our patient 2 became obese and 
there was a noticeable variation in insulin sensitivity 
measured by HOMAIR/HOMAS. However, the index 
of insulin secretion HOMAbeta was persistently less than 
100%, even when HOMAIR/HOMAS was 2.3/42.6%, 
suggesting failure in insulin secretion (Table 2). In 
both cases, but particularly in case 1, the stability of 
C-peptide plasma levels all over this period suggests sta-
bility of pancreatic beta-cell reserve in MODY2 (Table 
1), in contrast with the findings commonly observed 
in patients with DM2, and especially with DM1 (32).
It has been recently demonstrated in a cohort of 
healthy children aged 5-14 years who were enrolled in 
the Early Bird Diabetes study, that insulin resistance 
starts to rise in mid-childhood, some years before pu-
berty, mostly independent of rising adiposity and in-
sulin-simile growth factor-1 (IGF-1) (33). The condi-
tion of Patient 1 remained under control throughout 
his pubertal development, reinforcing the concept that 
hyperglycemia in MODY2 remains stable over time. 
Patient 2 has only recently initiated pubarche.
Another interesting aspect is the existence of a pos-
sible relationship between GCK mutation and growth 
retardation. Failure to thrive motivated the reference 
of Patient 2 to further investigation. Intrauterine 
growth retardation and reduced birth weight are clini-
cal manifestations frequently described in infants with 
permanent neonatal diabetes mellitus due to mutations 
in KCNJ11, ABCC8 (34), INS (35,36), PDX1 (37) 
genes, and in homozygous GCK mutations in children 
within the first few days of life (26,29), as a reflection of 
insulin deficiency in utero. Studies with GCK-MODY 
pedigrees demonstrated that GCK-MODY newborns 
are lighter than their unaffected siblings, independent 
of the parental origin of the mutation (38-40). Hat-
tersley and cols. (41) analyzed the impact caused by 
a heterozygous mutation in the GCK gene in fetal 
growth and birth weight of 58 children from 10 ex-
tended GCK pedigrees, and observed that the inheri-
tance of a GCK mutation by the fetus resulted in mean 
birth weight reduction of 533 g (p = 0.002). Length at 
birth was also reported in 26 children, and the presence 
of a fetal GCK mutation significantly reduced length 
(50.3 ± 5.3 vs. 55.5 ± 2.3 cm; p = 0.009). These studies 
brought evidence that birth weight is also determined 
by fetal genotype. Velho and cols. demonstrated that a 
large proportion of babies show early postnatal catch-
up after birth, as observed in our case 2. Also, they 
found that neither maternal nor fetal mutations alter 
adult height or weight of the offspring (42).
In conclusion, we described two Brazilian patients 
carrying mutations in the GCK gene, whose 9-year 
clinical follow-up confirmed the stability of metabolic 
control and absence of vascular complications without 
antidiabetic medications. We also report a novel non-
sense mutation p.Ser69Stop (c. 206C>G) associated 
with the MODY2 phenotype. This case report reinfor-
ces the importance of genetic diagnosis of monogenic 
forms of diabetes in order to establish prognosis and 
appropriate treatment intervention.
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